Diabetes mellitus: A common comorbidity increasing hemorrhagic transformation after tPA thrombolytic therapy for ischemic stroke

Jiang, Yinghua; Han, Jinrui; Spencer, Pierce; Li, Yadan; Vodovoz, Samuel J.; Ning, MingMing; Liu, Ning; Wang, Xiaoying; Dumont, Aaron S.

doi:10.1016/j.hest.2020.11.004

Cited by 9 publications

(4 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, the limited treatments for ischemic stroke include endorvascular surgery (called thrombectomy) or intravenous administration of alteplase (called thrombolysis) for the purpose of restoring blood flow [ 199 ]. However, due to the narrow therapeutic window, some contraindications, low efficacy to recanalize the large artery via thrombolysis, and even the reperfusion injury after recanalization, only a small percentage of ischemic patients can benefit from these two treatments [ 200 – 203 ]. Possibly inspired by replacement therapy for specific cells lost in NDs, recently there have been studies targeting different lost cell types in ischemic stroke to transplant specific cells for replacement to reconstruct damaged neural circuits [ 166 , 168 , 169 ].…”

Section: Therapeutic Potential Of Induced Directed Differentiation Of...mentioning

confidence: 99%

Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke

et al. 2023

View full text Add to dashboard Cite

Due to the limited capacity of the adult mammalian brain to self-repair and regenerate, neurological diseases, especially neurodegenerative disorders and stroke, characterized by irreversible cellular damage are often considered as refractory diseases. Neural stem cells (NSCs) play a unique role in the treatment of neurological diseases for their abilities to self-renew and form different neural lineage cells, such as neurons and glial cells. With the increasing understanding of neurodevelopment and advances in stem cell technology, NSCs can be obtained from different sources and directed to differentiate into a specific neural lineage cell phenotype purposefully, making it possible to replace specific cells lost in some neurological diseases, which provides new approaches to treat neurodegenerative diseases as well as stroke. In this review, we outline the advances in generating several neuronal lineage subtypes from different sources of NSCs. We further summarize the therapeutic effects and possible therapeutic mechanisms of these fated specific NSCs in neurological disease models, with special emphasis on Parkinson’s disease and ischemic stroke. Finally, from the perspective of clinical translation, we compare the strengths and weaknesses of different sources of NSCs and different methods of directed differentiation, and propose future research directions for directed differentiation of NSCs in regenerative medicine.

show abstract

Section: Therapeutic Potential Of Induced Directed Differentiation Of...mentioning

confidence: 99%

Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke

et al. 2023

View full text Add to dashboard Cite

show abstract

“…White matter lesions after brain hemorrhage are often associated with poor outcomes [238][239][240][241]. Neuroinflammation, oxidative stress, and excitotoxicity play a critical role in demyelination, axonal damage, and loss of oligodendrocytes after ICH [34,242,243]. In 2008, researchers first found that demyelination occurred inside and at the edge of the hematoma, and subsequently, neurons died [244].…”

Section: Hv1 Demyelination and Myelin Repair In Strokementioning

confidence: 99%

The Emerging Role of Microglial Hv1 as a Target for Immunomodulation in Myelin Repair

Tang,

Wu,

et al. 2023

Aging and disease

View full text Add to dashboard Cite

In the central nervous system (CNS), the myelin sheath ensures efficient interconnection between neurons and contributes to the regulation of the proper function of neuronal networks. The maintenance of myelin and the well-organized subtle process of myelin plasticity requires cooperation among myelin-forming cells, glial cells, and neural networks. The process of cooperation is fragile, and the balance is highly susceptible to disruption by microenvironment influences. Reactive microglia play a critical and complicated role in the demyelination and remyelination process. Recent studies have shown that the voltage-gated proton channel Hv1 is selectively expressed in microglia in CNS, which regulates intracellular pH and is involved in the production of reactive oxygen species, underlying multifaceted roles in maintaining microglia function. This paper begins by examining the molecular mechanisms of demyelination and emphasizes the crucial role of the microenvironment in demyelination. It focuses specifically on the role of Hv1 in myelin repair and its therapeutic potential in CNS demyelinating diseases.

show abstract

“…Treatment with an intravenous tissue-type plasminogen activator (tPA) is the only effective treatment in patients with acute ischemic stroke ( Ehrlich et al, 2019 ). However, in many clinical settings, the use of tPA in DS is either not beneficial or not recommended ( Jiang et al, 2021 ). Therefore, early diagnosis and novel therapeutics at sub-acute time points are essential for DS patients.…”

Section: Introductionmentioning

confidence: 99%

Mass spectrometry-based proteomic profiling of extracellular vesicle proteins in diabetic and non-diabetic ischemic stroke patients: a case-control study

Qadri,

Sohail,

Akhtar

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Acute ischemic stroke is the most common cause of neurologic dysfunction caused by focal brain ischemia and tissue injury. Diabetes is a major risk factor of stroke, exacerbating disease management and prognosis. Therefore, discovering new diagnostic markers and therapeutic targets is critical for stroke prevention and treatment. Extracellular vesicles (EVs), with their distinctive properties, have emerged as promising candidates for biomarker discovery and therapeutic application. This case-control study utilized mass spectrometry-based proteomics to compare EVs from non-diabetic stroke (nDS = 14), diabetic stroke (DS = 13), and healthy control (HC = 12) subjects. Among 1288 identified proteins, 387 were statistically compared. Statistical comparisons using a general linear model (log2 foldchange ≥0.58 and FDR-p≤0.05) were performed for nDS vs HC, DS vs HC, and DS vs nDS. DS vs HC and DS vs nDS comparisons produced 123 and 149 differentially expressed proteins, respectively. Fibrinogen gamma chain (FIBG), Fibrinogen beta chain (FIBB), Tetratricopeptide repeat protein 16 (TTC16), Proline rich 14-like (PR14L), Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKE), Biorientation of chromosomes in cell division protein 1-like 1 (BD1L1), and protein PR14L exhibited significant differences in the DS group. The pathway analysis revealed that the complement system pathways were activated, and blood coagulation and neuroprotection were inhibited in the DS group (z-score ≥2; p ≤ 0.05). These findings underscore the potential of EVs proteomics in identifying biomarkers for stroke management and prevention, warranting further clinical investigation.

show abstract

Diabetes mellitus: A common comorbidity increasing hemorrhagic transformation after tPA thrombolytic therapy for ischemic stroke

Cited by 9 publications

References 110 publications

Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke

Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke

The Emerging Role of Microglial Hv1 as a Target for Immunomodulation in Myelin Repair

Mass spectrometry-based proteomic profiling of extracellular vesicle proteins in diabetic and non-diabetic ischemic stroke patients: a case-control study

Contact Info

Product

Resources

About